Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis : Episode 9

Unmet Needs and the Role of AI in Earlier Disease Detection

August 30, 2024

Opinion

Video

Paul Noble, MD, provides his final thoughts surrounding unmet needs and breakthrough strategies for detection of IPF.

EP: 1.Symptoms, Manifestations and Mortality Rate of IPF

EP: 2.How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP: 3.Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP: 4.Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

EP: 5.Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis

EP: 6.Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

EP: 7.Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

EP: 8.The Roles of Biomarker Testing and HRCT in IPF and PPF

Now Viewing

EP: 9.Unmet Needs and the Role of AI in Earlier Disease Detection

EP: 10.Adverse Events Associated with Anti-Fibrotic Therapies

EP: 11.Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

EP: 12.The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

EP: 13.K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

Video content above is prompted by the following:

What are the key unmet needs in diagnosing IPF and PPF and how would you see AI impacting earlier detection of disease in the future?

Related Content

K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

MHE Staff

October 4th 2024

Article

Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.